
TSE:MFC
This summary was created by AI, based on 27 opinions in the last 12 months.
Manulife Financial (MFC) has shown a solid performance in recent quarters, buoyed by its strong presence in Asia and effective wealth management strategies. However, there are concerns regarding its valuation, as it is perceived to be somewhat overbought, trading over 2x book value with limited earnings growth expected in the near future. Despite these concerns, many experts highlight its decent dividend yield and ongoing growth potential, particularly in its Asian markets. The recent implementation of a tax on MFC products for mainland Chinese residents adds a layer of uncertainty. Overall, the sentiment among analysts is cautiously optimistic, with a call for careful monitoring of market conditions and potential entry points for investment.
This company is still a little bit levered to the market, so if you believe the market is going up, you step into this. If you don’t, then you go to another insurer. Has done quite well but recently broke its upward trend line and is going sideways. Major support is about $13 and if it breaks that support on the downside, it would then go down to about $12.50. If you own, you might want to hold it a little bit but this is not the seasonal time for this company.
Got fed up with the potential for their return going forward, which he thinks is going to be restricted because low interest rates are here for years and years to come. You can’t go too far wrong with this because valuation is cheap. Dividend is completely safe. ROE is coming back. Feels there are better opportunities in the financial space.
Has started to not do so well over the last little bit. Probably because of the great rotation of money coming out of bonds and going into stocks. However, sales growth has been very strong across all regions. Core earnings have been very good. Last quarter was not messy at all. However, they are having higher costs from new business strain. Probably a good buy at these levels.
Several issues with lifecos. With low interest rates, can they live up to their actuarial assumption? Also, exposure to the Europe bond market. Those things are probably behind them now so the question is, are they just good old solid financials now. In his mind, none of them stack up to being as good as the strongest bank.
Has done well over the last 3-4 months as they’ve hedged more and more of their exposure to both equity markets and interest-rates. Unhedged portion is certainly benefiting from the increase in markets globally. Still a reasonable multiple. Feels it is the best run Canadian insurance company. The particular attraction here is their growth in Asia. Dividend yield is modest but relatively secure at these levels.
In the early stages of a recovery. Stock has performed reasonably well in the last little while. From an earnings standpoint, have really re-engineered its business and gotten out of some of the riskier areas and focused again on growing in Asia and the US. Will return to some normal level of profitability this year, which more than covers the dividend and leaves room for growth. If interest rates start to rise, as he expects it will in 2014, all the lifecos will be huge beneficiaries.